Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: VRC01, VRC01LS, VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 5 Days
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Fort Lauderdale, Florida + 6 more

Conditions: HIV
Interventions: HXTC infusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Enfuvirtide-intensified HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV -1 Infection, HIV Infections
Interventions: PRO 140 (humanized monoclonal antibody to CCR5), Placebo Comparator; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Trimeris; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: HIV Infections, Cytopenias
Interventions: Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Human Immunodeficiency Virus Infections
Interventions: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 5
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions: Prevnar-13; Biological
Lead sponsor: VA Eastern Colorado Health Care System; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: HIV-1 Infection, HIV Infections
Interventions: PENNVAX-B; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infection
Interventions: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 73
States / cities: Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more

Conditions: HIV Infections
Interventions: MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • San Francisco, California

Conditions: HIV Infections
Interventions: VH4004280, Placebo, VH4011499; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • New York, New York + 2 more

Conditions: HIV Infections
Interventions: Raltegravir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more

Conditions: HIV Infections
Interventions: Hydroxyurea, Abacavir sulfate, Efavirenz, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 19 more

Conditions: HIV-1 Infections
Interventions: dapivirine 4789, dapivirine gel 4759, Drug placebo; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV-1-infection
Interventions: Albuvirtide, 3BNC117, Baseline ART; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more

Search by objective public record fields.

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Study of T-20 in HIV-Positive Adults

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

Safety and Efficacy Study of Switching From Epzicom to Truvada

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

The Biology of HIV Transmission

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study